3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
3
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
CNS
1
Breast
1
Conditions
Thymus Neoplasms
2
Mesothelioma
2
Lung Neoplasms
2
Adenocarcinoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
pembrolizumab
12
Nivolumab
6
atezolizumab
3
Ipilimumab
3
tislelizumab
2
spartalizumab
2
durvalumab
2
avelumab
2
Etoposide
2
ruxolitinib
1
poly ICLC
1
obinutuzumab
1
naptumomab estafenatox
1
milademetan
1
epacadostat
1
enzalutamide
1
entinostat
1
cemiplimab
1
budigalimab
1
bemcentinib
1
Thrombopoietin
1
Sirolimus
1
Quality of Life
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Levoleucovorin
1
Leucovorin
1
LY2940680
1
Interleukin-2
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Quality of Life
×
Other solid neoplasm
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled